p38 MAPK inhibition decreases TNF-α production and enhances postischemic human myocardial function

Journal of Surgical Research

Volumn 83, Issue 1, 1999, Pages 7-12

  Cain, Brian S ^a   Meldrum, Daniel R ^a   Meng, Xianzhong ^a   Dinarello, Charles A ^a   Shames, Brian D ^a   Banerjee, Anirban ^a   Harken, Alden H ^a  

^a NONE

Author keywords

Cardiac preconditioning; Inflammation; Sepsis; Trabeculae

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA;

CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN TISSUE; INFLAMMATION; PRIORITY JOURNAL; REOXYGENATION; REPERFUSION; SIGNAL TRANSDUCTION;

EID: 0033134116     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1998.5548     Document Type: Conference Paper

References (52)

1. Meldrum D. R. Tumor necrosis factor in the heart. Am. J. Physiol. 274:1998;R577.
2. Cain B. S., Meldrum D. R., Dinarello C. A., Meng X., Banerjee A., Harken A. H. Adenosine reduces cardiac TNF-α production and human myocardial injury following ischemia-reperfusion. J. Surg. Res. 76:1998;117.
3. Meldrum D. R., Cleveland J. C., Cain B. S., Shames B. D., Meng X., Bannerjee A., Harken A. H. Ischemic preconditioning downregulates post-ischemic myocardial tumor necrosis factor-α production: potential ultimate effector mechanism of preconditioning. Circulation. 98:1998;II214.
4. Meldrum D. R., Cleveland J. C., Cain B. S., Meng X., Harken A. H. Increased myocardial TNFα in a crystalloid perfused model of cardiac ischemia-reperfusion injury. Ann. Thorac. Surg. 65:1998;439.
5. Meldrum D. R. Mechanisms of cardiac preconditioning: Ten years after the discovery of ischemic preconditioning. J. Surg. Res. 73:1998;1.
6. Meldrum D. R., Dinarello C. A., Meng X., Shapiro L., Harken A. H. P38 MAP kinase-mediated myocardial TNFα production contributes to post-ischemic cardiac dysfunction. Circulation. 96:1997;I-556.
7. Meldrum D. R., Cain B. S., Cleveland J. C., Meng X., Ayala A., Harken A. H. Adenosine decreases post-ischemic myocardial TNFα: Implications for preconditioning and transplatation. Immunology. 92:1997;472.
8. Meldrum D. R., Dinarello C. A., Cleveland J. C., Cain B. S., Shames B. D., Meng X., Harken A. H. Hydrogen peroxide induces tumor necrosis factor α-mediated cardiac injury by a P38 mitogen-activated protein kinase-dependent mechanism. Surgery. 124:1998;291.
9. Cain B. S., Meldrum D. R., Harken A. H. PKC in normal and pathologic myocardial states. J. Surg. Res. 81:1999;249.
10. Cain, B. S. Meldrum, D. R. Dinarello, C. A. Meng, X. Banerjee, A. Harken, A. H. TNF-α and IL-1β synergistically depress human myocardial function, Crit. Care Med.
11. Kumar A., Thota V., Dee L., Olson J., Uretz E., Parrillo J. E. Tumor necrosis factor-alpha and interleukin 1-beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J. Exp. Med. 3:1996;949.
12. Finkel M. S., Oddis C. V., Jacob T. D., Watkins S. C., Hattler B. G., Simmons R. L. Negative notropic effects of cytokines on the heart mediated by nitric oxide. Science. 257:1992;387.
13. Bogoyevitch M. A., Gillespie-Brown J., Ketterman A. J., Fuller S. J., Ben-Levy R., Ashworth A., Marshall C. J., Sugden P. H. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. Circ. Res. 79:1996;162.
14. Lee J. C., Young P. R. Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J. Leukocycte Biol. 59:1996;152.
15. Cleveland J. C., Wollmering M. M., Meldrum D. R., Rowland R. T., Rehring T. F., Sheridan B. C., Harken A. H., Banerjee A. Ischemic preconditioning in human and rat ventricle. Am. J. Physiol. 271:1996;H1786.
16. Cleveland J. C., Meldrum D. R., Rowland R. T., Banerjee A., Harken A. H. Adenosine preconditioning of human myocardium is mediated through KATP channel activation. Surg. Forum. 48:1996;209.
17. Cleveland J. C., Meldrum D. R., Rowland R. T., Sheridan B. C., Banerjee A., Harken A. H. The obligate role of protein kinase C in mediating clinically accessible cardiac preconditioning. Surgery. 120:1996;345.
18. Cleveland J. C., Meldrum D. R., Cain B. S., Banerjee A., Harken A. H. Oral sulfonylurea agents prevent ischemic preconditioning in human myocardium. Circulation. 96:1997;29.
19. +. J. Mol. Cell. Cardiol. 29:1997;175.
20. Cain B. S., Meldrum D. R., Cleveland J. C., Meng X., Banerjee A., Harken A. H. The alpha and beta isoforms of protein kinase C mediate the human myocardial contractile response to exogenous calcium. Surg Forum. 48:1997;335.
21. Cain B. S., Meldrum D. R., Joo K. S., Davis R. J., Harken A. H. Diastolic hibernation masquerading as constrictive pericarditis. J. Card. Surg. 12:1997;235.
22. Cain B. S., Meldrum D. R., Meng X., Shames B. D., Banerjee A., Harken A. H. Calcium preconditioning in human myocardium. Ann. Thorac. Surg. 65:1998;1065.
23. Cain B. S., Meldrum D. R., Meng X., Pulido E. J., Banerjee A., Harken A. H. Therapeutic anti-dysrhythmic and functional protection in human atria. J. Surg. Res. 76:1998;143.
24. Cain B. S., Meldrum D. R., Joo K. S., Wang J. F., Meng X., Cleveland J. C., Banerjee A., Harken A. H. Human SERCA2a levels correlate inversely with age in senescent human myocardium. J. Am. Coll. Cardiol. 32:1998;458.
25. Cain B. S., Meldrum D. R., Meng X., Shames B. D., Banerjee A., Harken A. H. Therapeutic L-type calcium channel blockade prevents ischemic preconditioning in human myocardium. Surg Forum. 49:1998;212.
26. Bethencourt D. M., Laks H. Importance of edema and compliance changes during 24 hours of preservation of the dog heart. J. Thorac. Cardiovasc. Surg. 81:1981;440.
27. Kapadia S., Lee J., Torre-Amione G., Birdsall H. H., Ma T. S., Mann D. L. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J. Clin. Invest. 96:1995;1042.
28. Wagner D. R., McTiernan C., Sanders V. J., Feldman A. M. Adenosine inhibits lipopolysaccharide-induced secretion of tumor necrosis factor-alpha in the failing human heart. Circulation. 97:1998;521.
29. Squadrito F., Altavilla D., Zingarelli B., Ioculano M., Calapai G., Campo G. M., Miceli A., Caputi A. P. Tumor necrosis factor involvement in ischaemia-reperfusion. Eur. J. Pharmacol. 237:1993;223.
30. Chandrasekar B., Colston J. T., Freeman G. L. Induction of proinflammatory cytokine and antioxidant enzyme gene expression following brief myocardial ischemia. Clin. Exp. Immunol. 108:1997;346.
31. Gurevitch J., Frolkis I., Yuhas Y., Paz Y., Matsa M., Mohr R., Yakirevich V. Tumor necrosis factor-alpha is released from the isolated heart undergoing ischemia and reperfusion. J. Am. Coll. Cardiol. 28:1996;247.
32. Herskowitz A. S., Choi S., Ansari A. A., Wesselingh S. Cytokine mRNA expression in the postischemic/reperfused myocardium. Am. J. Pathol. 146:1995;419.
33. Maury C. P., Teppo A. M. Circulating tumour necrosis factor-alpha (cachectin) in myocardial infarction. J. Intern. Med. 225:1989;333.
34. Casey W. F., Hauser G. J., Hannallah R. S., Midgley F. M., Kahn W. N. Circulating endotoxin and tumor necrosis factor during pediatric cardiac surgery. Crit. Care Med. 20:1992;1090.
35. Tracey K. J., Beutler B., Lowry S. F., Merryweather J., Wolpe S., Milsark I. W., Hariri R. J., Fahey T. J., Zentella A., Albert J. D., Shires G. T., Cerami A. Shock and tissue injury induced by recombinant human cachectin. Science. 234:1986;470.
36. Murray D. R., Freeman G. L. Tumor necrosis factor-alpha induces a biphasic effect on myocardial contractility in conscious dogs. Circ. Res. 78:1995;154.
37. Cain B. S., Meldrum D. R., Harken A. H., McIntyre R. C. Physiologic basis for anti-cytokine clinical trials in the treatment of sepsis. J. Am. Coll. Surg. 186:1998;337.
38. 2+2+. FEBS Lett. 376:1995;24.
39. Torre-Amione G., Kapadia S., Lee J., Bies R. D., Lebovitz R., Mann D. L. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 92:1995;1487.
40. Dinarello C. A. Biologic basis for Interleukin-1 in disease. Blood. 87:1996;2095.
41. Meldrum D. R., Cleveland J. C., Sheridan B. C., Rowland R. T., Banerjee A., Harken A. H. Cardiac surgical implications of calcium dyshomeostasis in the heart. Ann. Thorac. Surg. 61:1996;1273.
42. Last-Barney K., Homan C. A., Faanes R. B., Merluzzi V. J. Synergistic and overlapping activities of tumor necrosis factor-alpha and IL-1. J. Immunol. 141:1988;527.
43. Sabbadini R. A., Betto R., Teresi A., Fachechi-Cassano G., Salviati G. The effects of sphingosine on sarcoplasmic reticulum calcium release. J. Biol. Chem. 267:1992;15475.
44. Oral H., Dorn G. W., Mann D. L. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-α in the adult mamalian cardiac myocyte. J. Biol. Chem. 272:1997;4836.
45. Yin T., Sandhu G., Wolfgang C. D., Burrier A., Webb R. L., Rigel D. F., Hai T., Whelan J. Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney. J. Biol. Chem. 272:1997;19943.
46. Seko Y., Takahashi N., Tobe K., Kadowaki T., Yazaki Y. Hypoxia and hypoxia/reoxygenation activate p65PAK, p38 mitogen-activated protein kinase (MAPK), and stress-activated protein kinase (SAPK) in cultured rat cardiac myocytes. Biochem. Biophys. Res. Commun. 239:1997;840.
47. Clerk A., Fuller S. J., Michael A., Sugden P. H. Stimulation of "stress-regulated" mitogen activated protein kinases (stress-activated protein kinases/c-Jun N-terminal kinases and p38-mitogen-activated protein kinases) in perfused rat hearts by oxidative and other stresses. J. Biol. Chem. 273:1998;7228.
48. Young P. R., McLaughlin M. M., Kumar S., Kassis S., Doyle M. L., McNulty D., Gallagher T. F., Fisher S., McDonnell P. C., Carr S. A., Huddleston M. J., Seibel G., Porter T. G., Livi G. P., Adams J. L., Lee J. C. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J. Biol. Chem. 272:1997;12116.
49. Whitmarsh A. J., Yang S. H., Su M. S., Sharrocks A. D., Davis R. J. Role of p38 and JNK mitogen-activated protein kinases in the activation of ternary complex factors. Mol. Cell. Biol. 17:1997;2360.
50. Clerk A., Sugden P. H. The p38-MAPK inhibitor, SB 203580, inhibits cardiac stress-activated protein kinases/c-jun N-terminal kinases (SAPKs/JNKs). FEBS Lett. 426:1998;93.
51. Cleveland J. C., Meldrum D. R., Rowland R. T., Banerjee A., Harken A. H. Preconditioning and hypothermic cardioplegia protect human heart equally against ischemia. Ann. Thorac. Surg. 63:1997;147.
52. 1. Am. J. Physiol. 273:1997;H902.